EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies

LONDON & NEW YORK--(BUSINESS WIRE)--Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the completion of a successful $65 million Series A funding round. SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures. The Series A brings together an international team of executives and investors with an extensiv